Efficacy and safety of platelet-rich plasma intracavernous injection for patients with erectile dysfunction: A systematic review, meta-analysis, and meta-regression

IF 2.4 3区医学 Q2 UROLOGY & NEPHROLOGY

Asian Journal of Urology Pub Date : 2024-10-01 DOI:10.1016/j.ajur.2024.01.001

{"title":"Efficacy and safety of platelet-rich plasma intracavernous injection for patients with erectile dysfunction: A systematic review, meta-analysis, and meta-regression","authors":"","doi":"10.1016/j.ajur.2024.01.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Intracavernous injection might be offered to patients with erectile dysfunction (ED) who did not respond to the first-line oral treatment. Platelet-rich plasma (PRP) might offer improvement in erectile function since it contains numerous growth factors. This study aimed to evaluate the efficacy and safety of PRP intracavernous injection for patients with ED.</div></div><div><h3>Methods</h3><div>We conducted relevant literature searches on Cochrane Library, Medline, Scopus, and <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> databases using specific keywords. The results of continuous variables were pooled into the mean difference (MD) and dichotomous variables into the odds ratio along with 95% confidence interval (95% CI).</div></div><div><h3>Results</h3><div>A total of six studies were included. Our pooled analysis revealed that PRP intracavernous injection was associated with a significant increase in the erectile function domain of the International Index of Erectile Function at 1 month (MD 3.47 [95% CI 2.62–4.32], <em>p</em><0.00001, <em>I</em><sup>2</sup>=7%), 3 months (MD 3.19 [95% CI 2.25–4.12], <em>p</em><0.00001, <em>I</em><sup>2</sup>=0%), and 6 months (MD 3.21 [95% CI 2.30–4.13], <em>p</em><0.00001, <em>I</em><sup>2</sup>=0%) after the intervention when compared with baseline values. PRP was also superior to a placebo in terms of improvement in erectile function domain of the International Index of Erectile Function score at 1 month (MD 2.83, <em>p</em><0.00001), 3 months (MD 2.87, <em>p</em><0.00001), and 6 months (MD 3.20, <em>p</em><0.00001) post-intervention. The adverse events from PRP injection were only mild without any serious adverse events.</div></div><div><h3>Conclusion</h3><div>PRP intracavernous injection may offer benefits in improving erectile function in patients with ED with a relatively good safety profile.</div></div>","PeriodicalId":46599,"journal":{"name":"Asian Journal of Urology","volume":"11 4","pages":"Pages 545-554"},"PeriodicalIF":2.4000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Journal of Urology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2214388224000018","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

Intracavernous injection might be offered to patients with erectile dysfunction (ED) who did not respond to the first-line oral treatment. Platelet-rich plasma (PRP) might offer improvement in erectile function since it contains numerous growth factors. This study aimed to evaluate the efficacy and safety of PRP intracavernous injection for patients with ED.

Methods

We conducted relevant literature searches on Cochrane Library, Medline, Scopus, and ClinicalTrials.gov databases using specific keywords. The results of continuous variables were pooled into the mean difference (MD) and dichotomous variables into the odds ratio along with 95% confidence interval (95% CI).

Results

A total of six studies were included. Our pooled analysis revealed that PRP intracavernous injection was associated with a significant increase in the erectile function domain of the International Index of Erectile Function at 1 month (MD 3.47 [95% CI 2.62–4.32], p<0.00001, I²=7%), 3 months (MD 3.19 [95% CI 2.25–4.12], p<0.00001, I²=0%), and 6 months (MD 3.21 [95% CI 2.30–4.13], p<0.00001, I²=0%) after the intervention when compared with baseline values. PRP was also superior to a placebo in terms of improvement in erectile function domain of the International Index of Erectile Function score at 1 month (MD 2.83, p<0.00001), 3 months (MD 2.87, p<0.00001), and 6 months (MD 3.20, p<0.00001) post-intervention. The adverse events from PRP injection were only mild without any serious adverse events.

Conclusion

PRP intracavernous injection may offer benefits in improving erectile function in patients with ED with a relatively good safety profile.

查看原文本刊更多论文

富血小板血浆鞘膜内注射治疗勃起功能障碍患者的有效性和安全性：系统回顾、荟萃分析和荟萃回归

目的对于口服一线治疗无效的勃起功能障碍（ED）患者，可进行阴茎海绵体内注射。富血小板血浆（PRP）含有多种生长因子，可改善勃起功能。本研究旨在评估PRP海绵体内注射治疗ED患者的有效性和安全性。方法我们使用特定关键词在Cochrane Library、Medline、Scopus和ClinicalTrials.gov数据库中进行了相关文献检索。结果共纳入六项研究。我们的汇总分析表明，PRP鞘膜内注射与一个月后国际勃起功能指数（International Index of Erectile Function）中勃起功能域的显著增加有关（MD 3.47 [95% CI 2.62-4.32]，p<0.00001，I2=7%）、3个月（MD 3.19 [95% CI 2.25-4.12]，p<0.00001，I2=0%）和6个月（MD 3.21 [95% CI 2.30-4.13]，p<0.00001，I2=0%）后与基线值相比均有明显提高。在干预后 1 个月（MD 2.83，p<0.00001）、3 个月（MD 2.87，p<0.00001）和 6 个月（MD 3.20，p<0.00001）的国际勃起功能指数评分中，PRP 在勃起功能改善方面也优于安慰剂。结论 PRP 海绵体内注射可改善 ED 患者的勃起功能，且安全性相对较好。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Asian Journal of Urology UROLOGY & NEPHROLOGY-

CiteScore

4.00

自引率

3.80%

发文量

100

审稿时长

4 weeks

期刊介绍： Asian Journal of Urology (AJUR), launched in October 2014, is an international peer-reviewed Open Access journal jointly founded by Shanghai Association for Science and Technology (SAST) and Second Military Medical University (SMMU). AJUR aims to build a communication platform for international researchers to effectively share scholarly achievements. It focuses on all specialties of urology both scientifically and clinically, with article types widely covering editorials, opinions, perspectives, reviews and mini-reviews, original articles, cases reports, rapid communications, and letters, etc. Fields of particular interest to the journal including, but not limited to: • Surgical oncology • Endourology • Calculi • Female urology • Erectile dysfunction • Infertility • Pediatric urology • Renal transplantation • Reconstructive surgery • Radiology • Pathology • Neurourology.